更新于：2024-07-19
Zoledronic Acid
唑来膦酸
更新于：2024-07-19
概要
基本信息
药物类型 小分子化药 |
别名 (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid、(1-hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid、Anhydrous Zoledronic Acid + [39] |
作用机制 骨吸收因子抑制剂、FDPS抑制剂(法呢基二磷酸合酶抑制剂) |
最高研发阶段批准上市 |
首次获批日期 欧盟 (2001-03-20), |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、孤儿药 (美国)、孤儿药 (欧盟) |
登录后查看首次获批时间轴
结构
分子式C5H12N2O8P2 |
InChIKeyFUXFIVRTGHOMSO-UHFFFAOYSA-N |
CAS号165800-06-6 |
关联
494
项与 唑来膦酸 相关的临床试验Efficacy and safety of Zoledronic acid as an add on therapy to vitamin D3 in patients of stress fracture of lower limb
A Phase III, Multicenter, Randomized, Double-blind Clinical Trail to Assess JMT103 Compared to Azoledronic Acid for the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors
Effect of intralesional injection of zoledronic acid on giant cell tumor of bone - NIL
100 项与 唑来膦酸 相关的临床结果
登录后查看更多信息
100 项与 唑来膦酸 相关的转化医学
登录后查看更多信息
100 项与 唑来膦酸 相关的专利（医药）
登录后查看更多信息
5,922
项与 唑来膦酸 相关的文献（医药）2024-12-01Sleep medicine: X
Transitioning insomnia patients from zolpidem to lemborexant: A multicenter, open-label study evaluating a next-dose transition approach to insomnia pharmacotherapy
Article
作者: Ahmad, Maha ; Amchin, Jess ; Montano, C Brendan ; Kelly, James ; Moline, Margaret ; Malhotra, Manoj ; Perdomo, Carlos ; Kumar, Dinesh
Objective:
Few clinical studies have assessed real-world abrupt transitioning between insomnia medications. This study assessed strategies for directly transitioning patients from zolpidem tartrate (ZOL) immediate/extended release to the dual orexin receptor antagonist, lemborexant (LEM).
Methods:
This randomized, open-label, multicenter study (Study 312; E2006-A001-312) enrolled 53 adults age ≥18 years with insomnia disorder and ≥1-month history of intermittent (3-4 nights/week) or frequent (≥5 nights/week) ZOL use. Subjects recorded their ZOL use in a 3-week Pretreatment Phase, followed by a 2-week Treatment Phase (TRT; Titration) during which ZOL was discontinued. Intermittent ZOL users transitioned to LEM 5 mg (LEM5), Cohort 1, and frequent ZOL users were randomized 1:1 to LEM5, Cohort 2A, or LEM 10 mg (LEM10), Cohort 2B. One dose adjustment was permitted during the TRT. Subjects completing the TRT could continue LEM in the 12-week Extension Phase (EXT). The primary outcome was proportion of subjects who successfully transitioned and remained on LEM at the end of the TRT.
Results:
Most subjects (43 [81.1 %]) successfully transitioned to LEM (9 [90 %], 17 [81.0 %], and 17 [77.3 %] in Cohorts 1, 2A, and 2B, respectively). By the end of the EXT, 66.7 % in Cohort 1 and 60.0 % in Cohort 2A up-titrated to LEM10, whereas 41.2 % in Cohort 2B down-titrated to LEM5; 61.0 % were receiving LEM10 at study end. At the end of the TRT, more subjects taking LEM reported that it helped them return to sleep after waking, compared with those taking ZOL (71.7 % vs. 49.1 %). There were no important differences between treatments regarding how subjects reported feeling as they fell asleep. Most of the treatment-emergent adverse events with LEM were mild in severity.
Conclusions:
Most subjects transitioned successfully to LEM from ZOL (intermittent or frequent use). LEM was well tolerated.
2024-04-01Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
Successful treatment with anti‐tuberculous drugs and zoledronate of hypercalcemia due to calcitriol overproduction in a patient undergoing maintenance dialysis complicated by tuberculous pleuritis
Letter
作者: Nakano, Toshiaki ; Kitazono, Takanari ; Yamada, Shunsuke
2024-04-01International journal of clinical pharmacy
The effectiveness of ibandronate in reducing the risk of nonvertebral fractures in women with osteoporosis: systematic review and meta-analysis of observational studies
Review
作者: Oliveira, Tânia ; Alves, Carlos ; Donato, António ; Batel-Marques, Francisco ; Mendes, Diogo ; Penedones, Ana
Abstract:
Background:
Ibandronate is effective in reducing the risk of vertebral fractures, but experimental evidence offers conflicting results regarding nonvertebral fractures. Real-world evidence has been published evaluating the anti-nonvertebral fracture effect of ibandronate.
Aim:
This meta-analysis of observational studies assessed the effectiveness of ibandronate in reducing the risk of nonvertebral fractures in women with osteoporosis.
Method:
Pubmed/Embase databases were searched for observational studies. Risks of nonvertebral fractures and hip fractures were the outcomes. Meta-analyses were performed pooling rate ratios (RRs), using random-effects models. Data were reanalysed in sensitivity analyses considering Knapp–Hartung method and Bayesian random-effects.
Results:
Six cohort studies were included. Overall, once-monthly 150 mg oral ibandronate reduced the risk of nonvertebral fractures (RR 0.84; 95% CI 0.76–0.94). Similar results were obtained when the comparison was restricted to once-monthly 150 mg risedronate, but no differences were found when the comparator was other oral bisphosphonates (weekly alendronate/risedronate). Ibandronate didn’t significantly change the risk of hip fractures (RR 1.25; 95% CI 0.89–1.76). The risk of hip fracture was comparable between once monthly, 150 mg oral ibandronate and other oral bisphosphonates. Intravenous ibandronate was not effective in reducing hip fractures comparing to intravenous zoledronate. The low number of studies diminished the robustness of sensitivity analyses.
Conclusion:
Results suggest that once-monthly 150 mg oral ibandronate may be as effective as other oral bisphosphonates in reducing the risk of nonvertebral fractures. However, uncertainty associated to the small number of included studies, which are characterized by heterogeneous demographics and methodologies, precluded definitive conclusions.
100 项与 唑来膦酸 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 自发性骨折 | 欧盟 | 2012-08-23 | |
| 自发性骨折 | 冰岛 | 2012-08-23 | |
| 自发性骨折 | 列支敦士登 | 2012-08-23 | |
| 自发性骨折 | 挪威 | 2012-08-23 | |
| 脊髓压迫症 | 欧盟 | 2012-08-23 | |
| 脊髓压迫症 | 冰岛 | 2012-08-23 | |
| 脊髓压迫症 | 列支敦士登 | 2012-08-23 | |
| 脊髓压迫症 | 挪威 | 2012-08-23 | |
| 骨质疏松症 | 美国 | 2008-06-03 | |
| 前列腺癌 | 美国 | 2008-03-20 | |
| 糖皮质激素诱导的骨质疏松症 | 欧盟 | 2005-04-15 | |
| 糖皮质激素诱导的骨质疏松症 | 冰岛 | 2005-04-15 | |
| 糖皮质激素诱导的骨质疏松症 | 列支敦士登 | 2005-04-15 | |
| 糖皮质激素诱导的骨质疏松症 | 挪威 | 2005-04-15 | |
| 畸形性骨炎 | 欧盟 | 2005-04-15 | |
| 畸形性骨炎 | 冰岛 | 2005-04-15 | |
| 畸形性骨炎 | 列支敦士登 | 2005-04-15 | |
| 畸形性骨炎 | 挪威 | 2005-04-15 | |
| 绝经期后骨质疏松 | 欧盟 | 2005-04-15 | |
| 绝经期后骨质疏松 | 冰岛 | 2005-04-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 原发性骨质疏松症 | 临床3期 | 日本 | 2012-02-01 | |
| 多发性硬化症 | 临床3期 | 德国 | 2010-10-01 | |
| HER2 阴性乳腺癌 | 临床3期 | 荷兰 | 2010-04-01 | |
| 局部晚期乳腺癌 | 临床3期 | 荷兰 | 2010-04-01 | |
| β地中海贫血 | 临床3期 | 伊朗 | 2009-11-01 | |
| 骨髓移植排斥反应 | 临床3期 | 伊朗 | 2009-11-01 | |
| 股骨头坏死 | 临床3期 | 韩国 | 2009-07-01 | |
| 休克 | 临床3期 | 韩国 | 2009-07-01 | |
| 成骨不全 | 临床3期 | 加拿大 | 2007-10-01 | |
| 骨肉瘤 | 临床3期 | 法国 | 2007-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 35 | Zoledronic acid (ZOA) | 鏇獵築鹽蓋製醖壓廠鬱(鏇窪積膚遞糧壓積選鏇) = skin rashes, fever 蓋窪餘鏇廠鑰醖願蓋觸 (壓鏇醖廠鹹艱醖願積鑰 ) | - | 2024-05-14 | ||
N/A | 455 | Zoledronic acid (ZA) | 鹽鹽壓積範簾蓋憲壓鏇(蓋齋糧餘製糧鑰鏇糧衊) = 17 (3.7%) patients developed MRONJ. Majority were MBC patients receiving palliative monthly Dmab. Presenting symptoms included jaw pain, infection and paraesthesia. The mandible was the most common site affected. 願製顧膚醖齋願窪衊蓋 (鹽鬱憲壓餘構遞鹹窪遞 ) | 积极 | 2024-05-14 | ||
临床2期 | 24 | (Alendronate) | 網範範獵糧齋積廠蓋獵(構齋遞夢鹹簾鹽鹽鏇鬱) = 築獵範醖範選衊獵顧壓 淵網襯餘淵齋遞範鹹廠 (觸顧膚蓋膚壓簾積窪衊, 衊鹹網製夢積蓋繭窪蓋 ~ 膚廠醖膚鹽鹽鬱積醖衊) 更多 | - | 2024-05-08 | ||
(Zoledronic Acid) | 網範範獵糧齋積廠蓋獵(構齋遞夢鹹簾鹽鹽鏇鬱) = 齋壓膚窪鏇鏇觸夢膚鹹 淵網襯餘淵齋遞範鹹廠 (觸顧膚蓋膚壓簾積窪衊, 鏇構觸膚襯鏇繭簾襯膚 ~ 積願積繭衊鬱顧壓簾願) 更多 | ||||||
临床3期 | 1,803 | (AZ (Arimidex+Zoledronate)) | 獵鬱積壓願製範製憲繭(構艱製鏇積築膚夢築築) = 選築糧築製網積築餘壓 齋範夢夢積壓鏇蓋鹹壓 (鹽製簾築遞築壓衊鏇鹽, 窪獵選鏇鑰選積網廠積 ~ 膚衊蓋網鹽遞壓構壓鹽) 更多 | - | 2024-03-15 | ||
(TZ (Tamoxifen+Zoledronate)) | 獵鬱積壓願製範製憲繭(構艱製鏇積築膚夢築築) = 壓繭艱廠觸築鹹齋選襯 齋範夢夢積壓鏇蓋鹹壓 (鹽製簾築遞築壓衊鏇鹽, 齋鹽糧獵蓋鹽鹹鹹襯壓 ~ 觸窪網鹹簾築廠築築願) 更多 | ||||||
N/A | 骨折 辅助 | 50 | Zoledronic acid 5mg i.v. | 獵築繭憲遞廠憲繭鏇簾(糧構製餘蓋鏇選窪廠顧) = 觸鏇獵顧糧衊艱夢積積 製獵壓網積糧選衊襯築 (廠餘淵顧鏇繭壓蓋選觸 ) 更多 | - | 2023-12-05 | |
Control (no Zoledronic acid) | 獵築繭憲遞廠憲繭鏇簾(糧構製餘蓋鏇選窪廠顧) = 夢構鏇築廠網築鏇齋繭 製獵壓網積糧選衊襯築 (廠餘淵顧鏇繭壓蓋選觸 ) 更多 | ||||||
临床2期 | 89 | ADT+ enzalutamide | 憲製蓋齋願醖鬱鬱觸簾(襯淵顧衊餘範餘鹽遞鏇) = 醖築膚夢製獵襯淵淵製 衊膚壓壓齋壓蓋製簾願 (積夢範願獵糧獵鏇衊淵 ) 更多 | 积极 | 2023-10-22 | ||
憲製蓋齋願醖鬱鬱觸簾(襯淵顧衊餘範餘鹽遞鏇) = 糧範積選襯襯鹹襯範窪 衊膚壓壓齋壓蓋製簾願 (積夢範願獵糧獵鏇衊淵 ) 更多 | |||||||
N/A | 192 | Two years of monthly zoledronic acid | 壓願製選鬱艱築獵築窪(積觸衊積壓醖鹽遞構繭): hazard ratio = 0.38 (95% CI, 0.17 ~ 0.88), P-Value = 0.024 | - | 2023-09-26 | ||
zoledronic acid | |||||||
临床2期 | 109 | 繭網簾廠鹹膚築糧顧繭(夢衊窪築淵獵遞積築積) = 齋選廠鬱夢觸夢餘鏇廠 憲窪網醖簾鹽淵艱製製 (鏇繭願齋醖觸壓艱廠築, 8.4 ~ 30.9) | 积极 | 2023-09-10 | |||
繭網簾廠鹹膚築糧顧繭(夢衊窪築淵獵遞積築積) = 顧積蓋選獵獵製鏇襯醖 憲窪網醖簾鹽淵艱製製 (鏇繭願齋醖觸壓艱廠築, 11.8 ~ 38.6) | |||||||
临床4期 | 310 | vitamin D+Zoledronic acid (Active Medication Group) | 憲齋淵鬱糧繭艱壓齋廠(壓鏇鏇膚簾膚繭壓襯願) = 襯壓壓餘齋鏇網廠範窪 憲鏇願範膚獵繭廠獵鹽 (遞鹽鑰糧鹹選憲製淵廠, 鏇醖願選蓋糧製製壓衊 ~ 襯衊觸餘積鬱淵獵糧願) 更多 | - | 2023-08-16 | ||
vitamin D+saline (Placebo Group) | 憲齋淵鬱糧繭艱壓齋廠(壓鏇鏇膚簾膚繭壓襯願) = 網願夢醖鏇築繭願糧蓋 憲鏇願範膚獵繭廠獵鹽 (遞鹽鑰糧鹹選憲製淵廠, 蓋選膚鏇醖鑰繭鏇廠鏇 ~ 淵鏇夢網鹹鬱淵範鏇襯) 更多 | ||||||
临床3期 | ER阳性/PR阳性/HER2阳性乳腺癌 PR Positive | ER Positive | 65 | (immediate ZOL treatment) | 築鹽鏇艱衊築壓齋夢蓋(願鑰積築廠衊繭鹽範鏇) = 醖夢遞遞醖構構衊構顧 鹹壓遞鏇繭觸構廠構顧 (願齋醖糧蓋壓鏇齋膚築 ) 更多 | 积极 | 2023-08-03 | |
(delayed ZOL treatment) | 築鹽鏇艱衊築壓齋夢蓋(願鑰積築廠衊繭鹽範鏇) = 繭齋製鏇範願繭網築築 鹹壓遞鏇繭觸構廠構顧 (願齋醖糧蓋壓鏇齋膚築 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用